Jump to ContentJump to Main Navigation
Show Summary Details

Open Medicine

formerly Central European Journal of Medicine

Editor-in-Chief: Darzynkiewicz, Zbigniew

1 Issue per year


IMPACT FACTOR increased in 2015: 0.190
5-year IMPACT FACTOR: 0.221

SCImago Journal Rank (SJR) 2015: 0.140
Source Normalized Impact per Paper (SNIP) 2015: 0.154
Impact per Publication (IPP) 2015: 0.197

Open Access
Online
ISSN
2391-5463
See all formats and pricing



Select Volume and Issue

Issues

The latent cytomegalovirus decreases telomere length by microcompetition

Hanan Polansky
  • The Center for the Biology of Chronic Disease (CBCD), Valley Cottage, NY 10989, USA
/ Adrian Javaherian
  • The Center for the Biology of Chronic Disease (CBCD), Valley Cottage, NY 10989, USA
Published Online: 2015-05-27 | DOI: https://doi.org/10.1515/med-2015-0042

Abstract

Reduced telomere length has been associated with aging and age-related diseases. Latent infection with the Cytomegalovirus (CMV) induces telomere shortening in the infected cells. Latent CMV infection may cause reduced telomere length via GABP transcription factor deficiency, according to the Microcompetition Theory. Microcompetition and viral-induced transcription factor deficiency is important since most people harbor a latent viral infection.

Keywords: Latent virus; microcompetition; transcription factor; telomere

References

  • [1] Drury S.S., Theall K., Gleason M.M., Smyke A.T., De Vivo I., Wong J.Y.Y. et al., Telomere length and early severe social deprivation: linking early adversity and cellular aging, Mol. Psychiatry, 2012, 17(7), 719-727 [Crossref]

  • [2] van de Berg P.J., Griffiths S.J., Yong S.L., Macaulay R., Bemelman F.J., Jackson S. et al., Cytomegalovirus Infection Reduces Telomere Length of the Circulating T Cell Pool, J. Immunol. 2010, 184, 3417-3423 [Web of Science]

  • [3] Polansky H., Microcompetition with Foreign DNA and the Origin of Chronic Disease., The Center for the Biology of Chronic Disease, New York, 2003

  • [4] Liu B.H., Wang X., Ma Y.X., Wang S., CMV Enhancer/Human PDGF-Beta Promoter for Neuron-Specific Transgene Expression, Gene Ther., 2004, 11(1), 52-60 [Crossref]

  • [5] Slobedman B., Mocarski E.S., Quantitative Analysis of Latent Human Cytomegalovirus, J. Virol., 1999, 73(6), 4806-4812

  • [6] Adam G.I., Miller S.J., Ulleras E., Franklin G.C., Cell-Type- Specific Modulation of PDGF-B Regulatory Elements via Viral Enhancer Competition: A Caveat for the Use of Reference Plasmids in Transient Transfection Assays, Gene, 1996, 178(1), 25-29

  • [7] Yu S., Cui K., Jothi R., Zhao D.M., Jing X., Zhao K. et al., GABP controls a critical transcription regulatory module that is essential for maintenance and differentiation of hematopoietic stem/progenitor cells, Blood, 2011, 117(7), 2166-2178 [Web of Science]

  • [8] Sarek G., Vannier J.B., Panier S., Petrini J.H.J., Boulton S.J., TRF2 Recruits RTEL1 to Telomeres in S Phase to Promote T-Loop Unwinding, Molecular Cell, 2015, 57(4), 622-635 [Crossref]

  • [9] Spyridopoulos I., Hoffmann J., Aicher A., Brummendorf T.H., Doerr H.W., Zeiher A.M. et al., Accelerated Telomere Shortening in Leukocyte Subpopulations of Patients With Coronary Heart Disease, Circulation, 2009, 120, 1364-1372 [Web of Science]

  • [10] Nan W.Q., Ling Z., Bing C., The influence of the telomeretelomerase system on diabetes mellitus and its vascular complications, Expert Opin. Ther. Targets., 2015, 19(6)

  • [11] Ji Y.N., An L., Zhan P., Chen X.H., Cytomegalovirus infection and coronary heart disease risk: a meta-analysis, Molecular Biology Reports, 2012, 39(6), 6537-6546 [Web of Science] [Crossref]

  • [12] Mendy A., Gasana J., Vieira E.R., Diallo H., Prospective study of cytomegalovirus seropositivity and risk of mortality from diabetes, Acta Diabetol., 2014, 51, 723-729 [Web of Science]

  • [13] Green M., Michaels M.G., Epstein-Barr Virus Infection and Posttransplant Lymphoproliferative Disorder, Am. J. Transplant., 2013, 13(s3), 41-54 [Crossref] [Web of Science]

  • [14] Reddehase M.J., Cytomegaloviruses: From Molecular Pathogenesis to Intervention. Volume 2, Horizon Scientific Press, United Kingdom, 2013

  • [15] Bernstein D.I., Bellamy A.R., Hook III E.W., Levin M.J., Wald A., Ewell M.G. et al., Epidemiology, Clinical Presentation, and Antibody Response to Primary Infection With Herpes Simplex Virus Type 1 and Type 2 in Young Women, Clin. Infect. Dis., 2013, 56(3), 344-351 [Crossref]


Received: 2015-04-26

Accepted: 2015-04-30

Published Online: 2015-05-27


Citation Information: Open Medicine. Volume 10, Issue 1, ISSN (Online) 2391-5463, DOI: https://doi.org/10.1515/med-2015-0042, May 2015

© 2015 Hanan Polansky, Adrian Javaherian. This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License. (CC BY-NC-ND 3.0)

Comments (1)

Please log in or register to comment.
  • The CBCD came out with a new video explaining this paper to the general public. The link is below. https://www.youtube.com/watch?v=2UYTvVbi9rA

    posted by: Adrian Javaherian on 2015-12-02 12:03 PM (Europe/Berlin)